Quantcast

Latest Boehringer Ingelheim Stories

2014-05-29 16:26:15

Boehringer Ingelheim agrees to pay $650 Million to compensate the nearly 4,000 individuals who allege they were injured as a result of Pradaxa usage. CHICAGO, May 29, 2014 /PRNewswire/ -- TorHoerman Law is pleased to announce that the Pradaxa litigation that it has helped lead since before the Multi-District Litigation (MDL) was formed is set to be resolved by settlement. Boehringer Ingelheim, which manufactures the drug, and lead plaintiffs' counsel, including Tor Hoerman, reached...

2014-05-28 23:04:24

Roger C. Denton, Plaintiffs' Co-Lead Counsel and a lead negotiator in the Pradaxa® MDL, reports that a $650 Million settlement has been reached today with Boehringer Ingelheim Pharmaceuticals, Inc. (and affiliates) to settle approximately 4,000 Pradaxa® claims. St. Louis, MO (PRWEB) May 28, 2014 The Plaintiffs’ Steering Committee, appointed by The Honorable Chief Judge David R. Herndon to negotiate the settlement on behalf of all plaintiffs in the Pradaxa® MDL, and...

2014-05-28 23:01:48

Seth A. Katz and Burg Simpson Eldredge Hersh & Jardine, P.C. are pleased to announce that earlier today Boehringer Ingelheim Pharmaceuticals, Inc. and its related companies agreed to pay $650,000,000 to settle close to 4,000 claims brought on behalf of individuals who were injured after taking the company’s anticoagulant drug, Pradaxa (dabigatran etexilate). (PRWEB) May 28, 2014 Denver, Colorado: Seth A. Katz and Burg Simpson Eldredge Hersh & Jardine, P.C. are pleased to...

2014-05-28 08:31:29

RIDGEFIELD, Conn., May 28, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) announced today that it has reached a comprehensive settlement of state and federal cases in the U.S. litigation regarding Pradaxa® (dabigatran etexilate mesylate) in the amount of $650 million. "Time and again, the benefits and safety of PRADAXA have been confirmed," said Desiree Ralls-Morrison, senior vice president and general counsel, Boehringer Ingelheim USA Corporation. "BI stands resolutely behind PRADAXA and...

2014-05-28 08:30:28

BEDFORD, Ohio, May 28, 2014 /PRNewswire/ -- Ben Venue Laboratories. Inc. ("Ben Venue"), a member of the Boehringer Ingelheim Group of Companies, announced today that the company has signed an asset purchase agreement for the sale of the assets of Bedford Laboratories, Ben Venue's U.S. injectable generics business to Hikma Pharmaceuticals PLC ("Hikma"). Bedford Laboratories is a leading provider of generic sterile injectable medicines in the U.S., with a focus on acute-care hospitals,...

2014-05-23 08:23:45

European Commission approves third product from the Boehringer Ingelheim and Lilly Diabetes alliance RIDGEFIELD, Conn. and INDIANAPOLIS, May 23, 2014 /PRNewswire/ -- The European Commission granted marketing authorization for Jardiance(®) (empagliflozin) tablets, a sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of type 2 diabetes mellitus (T2D) to improve glycemic control in adults in Europe, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company...

2014-05-18 16:20:52

-- Two Phase 3 trials met primary endpoint of reduction in annual rate of lung function decline RIDGEFIELD, Conn., May 18, 2014 /PRNewswire/ -- Boehringer Ingelheim announced the results of its two pivotal Phase 3 INPULSIS(TM) trials (INPULSIS(TM)-1 and -2; NCT01335464 and NCT01335477), which were published online today in the New England Journal of Medicine (NEJM). The INPULSIS(TM) trials evaluated the efficacy and safety of nintedanib, an investigational therapy being studied in people with...

2014-05-15 12:36:22

RIDGEFIELD, Conn. and INDIANAPOLIS, May 15, 2014 /PRNewswire/ -- Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D), Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) announced. Additionally, similar proportions of patients in...

2014-04-30 12:30:17

- First results of the pivotal Phase 3 INPULSIS(TM) trials investigating the efficacy and safety of nintedanib, an investigational compound, in the treatment of idiopathic pulmonary fibrosis (IPF) RIDGEFIELD, Conn., April 30, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today that the first results from two highly anticipated Phase 3 trials in idiopathic pulmonary fibrosis (IPF) and in chronic obstructive pulmonary disease (COPD) will be presented at the 2014 American...

2014-04-29 16:29:38

DUBLIN, Apr. 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/557vt9/life_sciences_bpo) has announced the addition of the "Life Sciences BPO Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 The life sciences BPO market comprises services offered by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs)...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related